Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
318
-
Total 13F shares, excl. options
-
89.5M
-
Shares change
-
+849K
-
Total reported value, excl. options
-
$6.37B
-
Value change
-
-$87.2M
-
Put/Call ratio
-
0.66
-
Number of buys
-
161
-
Number of sells
-
-195
-
Price
-
$71.41
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q4 2018
437 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q4 2018.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 318 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 89.5M shares
of 99.6M outstanding shares and own 89.82% of the company stock.
Largest 10 shareholders include FMR LLC (13M shares), JANUS HENDERSON GROUP PLC (8.81M shares), Vanguard Group Inc (8.08M shares), BlackRock Inc. (4.98M shares), PERCEPTIVE ADVISORS LLC (4.61M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.01M shares), Capital International Investors (3.53M shares), BB BIOTECH AG (3.34M shares), Invesco Ltd. (2.13M shares), and FRANKLIN RESOURCES INC (2.02M shares).
This table shows the top 318 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.